Polydeoxyribonucleotide (PDRN)

Definition

Polydeoxyribonucleotide (PDRN) is a naturally derived biopolymer consisting of a heterogeneous mixture of double-stranded DNA fragments with molecular weights between 50 and 1500 kilodaltons (kDa). It is extracted from the sperm cells of selected salmon species and purified to remove all protein and lipid contaminants. PDRN is classified as a tissue repair agent and is used in injectable form for regenerative and aesthetic medical applications.

Molecular Structure

PDRN retains the canonical double-helix structure of B-form DNA, composed of deoxyribonucleotide monomers linked by 3'-5' phosphodiester bonds. Each monomer consists of a deoxyribose sugar, a phosphate group, and one of four nitrogenous bases (adenine, thymine, guanine, or cytosine). The fragments are too short to encode functional genes but maintain the structural features necessary for receptor binding and enzymatic recognition by endogenous nucleases.

Mechanism of Action

PDRN acts through two complementary pathways. First, intact PDRN chains bind to adenosine A2A receptors on fibroblasts, endothelial cells, and inflammatory cells, activating cAMP-dependent signaling that promotes cell proliferation, collagen synthesis, angiogenesis, and anti-inflammatory responses. Second, as tissue nucleases degrade PDRN fragments, the released nucleotides and nucleosides enter the salvage pathway, providing metabolic substrates for DNA and RNA synthesis in metabolically stressed cells.

Clinical Applications

PDRN is used in aesthetic medicine as a skin booster for facial rejuvenation, scar remodeling, and periorbital revitalization. In regenerative medicine, it is applied for wound healing acceleration, treatment of diabetic and ischemic ulcers, and post-surgical recovery. Orthopedic applications include tendon repair and cartilage regeneration.

History

PDRN was first characterized pharmacologically in the late 1980s by Italian researchers investigating nucleotide metabolism. The discovery of its A2A receptor agonist activity in the early 2000s provided a mechanistic framework for its tissue-regenerative effects. Korean manufacturer Pharmaresearch Products launched Rejuran Healer in 2014, pioneering the use of PDRN as an aesthetic skin booster and igniting widespread adoption across Asia.